Ieq Capital LLC bought a new stake in Accolade, Inc. (NASDAQ:ACCD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,114,691 shares of the company's stock, valued at approximately $13,387,000. Ieq Capital LLC owned approximately 1.44% of Accolade as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also made changes to their positions in the company. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Accolade by 111.1% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,798,993 shares of the company's stock worth $19,033,000 after acquiring an additional 946,970 shares during the last quarter. ARK Investment Management LLC raised its holdings in Accolade by 12.6% during the 4th quarter. ARK Investment Management LLC now owns 6,805,208 shares of the company's stock worth $81,731,000 after purchasing an additional 762,685 shares during the last quarter. JFG Wealth Management LLC acquired a new position in Accolade during the 4th quarter valued at about $5,657,000. HighTower Advisors LLC bought a new position in shares of Accolade in the 3rd quarter valued at about $2,354,000. Finally, Vanguard Group Inc. grew its position in shares of Accolade by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,283,858 shares of the company's stock worth $55,903,000 after buying an additional 157,464 shares during the period. 84.99% of the stock is owned by institutional investors.
Accolade Stock Performance
Shares of ACCD stock remained flat at $7.21 on Monday. The stock had a trading volume of 463,086 shares, compared to its average volume of 736,855. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.64 and a quick ratio of 2.64. The stock has a market cap of $564.98 million, a price-to-earnings ratio of -5.44 and a beta of 2.15. Accolade, Inc. has a 52 week low of $6.33 and a 52 week high of $15.36. The business has a fifty day moving average of $8.99 and a 200-day moving average of $9.97.
Accolade (NASDAQ:ACCD - Get Free Report) last posted its quarterly earnings data on Thursday, April 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.53%. The company had revenue of $124.80 million for the quarter, compared to the consensus estimate of $123.91 million. During the same period last year, the company earned ($0.42) earnings per share. The firm's revenue was up 26.1% compared to the same quarter last year. As a group, research analysts forecast that Accolade, Inc. will post -1.24 EPS for the current fiscal year.
Wall Street Analyst Weigh In
ACCD has been the topic of a number of recent research reports. SVB Leerink assumed coverage on shares of Accolade in a research note on Monday, February 26th. They issued an "outperform" rating and a $16.00 price objective on the stock. Guggenheim reduced their price target on Accolade from $17.00 to $13.00 and set a "buy" rating on the stock in a research report on Wednesday, May 8th. Needham & Company LLC dropped their price objective on Accolade from $17.00 to $13.00 and set a "buy" rating for the company in a report on Friday, April 26th. Morgan Stanley cut their target price on Accolade from $13.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Friday, April 26th. Finally, Truist Financial decreased their target price on Accolade from $16.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, April 26th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $14.14.
Get Our Latest Report on ACCD
About Accolade
(
Free Report)
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.
Read More
Want to see what other hedge funds are holding ACCD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accolade, Inc. (NASDAQ:ACCD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Accolade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.
While Accolade currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
